Optellum

Optellum, based in Oxford and founded in 2016, is the company with the first FDA-cleared AI for judging whether a lung nodule on CT is likely to be cancer. Its Virtual Nodule Clinic, cleared under 510(k) in 2021 and CE-marked, combines a deep-learning Lung Cancer Prediction score with nodule management software, and it is used in NHS trusts and US health systems and in partnership with Johnson & Johnson's lung cancer initiative. OnCo links it to non-small-cell lung cancer, AI in radiology and low-dose CT lung screening, and to the product record. Whether an AI malignancy score reduces unnecessary biopsies without missing cancers is the question its deployments will answer. The Virtual Nodule Clinic has its own page.